Literature DB >> 19188480

Lupus update: perspective and clinical pearls.

Susan Manzi1.   

Abstract

Patients with systemic lupus erythematosus (SLE, lupus) have a markedly better survival rate today than they did 50 years ago, but they face a greater risk of cancer, cardiovascular disease, and osteoporosis at early ages. With better understanding of the immunological mechanisms of the disease, new avenues of therapy are emerging.

Entities:  

Mesh：

Year:  2009        PMID： 19188480     DOI： 10.3949/ccjm.76a.gr005

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  5 in total

1.  [A wolf in sheep's clothing: atypical systemic lupus erythematosus (SLE) presenting as cardiovascular disease].

Authors:  Ingo H Tarner; Uwe Lange; Katharina Madlener; Katharina Classen; Reinhard Kandolf; Johannes Sperzel; Ulf Müller-Ladner
Journal:  Med Klin (Munich)       Date:  2010-04

2.  The involvement of T regulatory lymphocytes in a cohort of lupus nephritis patients: a pilot study.

Authors:  Antonella Afeltra; Antonietta Gigante; Domenico Paolo Emanuele Margiotta; Chiara Taffon; Rosario Cianci; Biagio Barbano; Marta Liberatori; Antonio Amoroso; Filippo Rossi Fanelli
Journal:  Intern Emerg Med       Date:  2015-02-27       Impact factor: 3.397

3.  Manifestations of systemic lupus erythematosus.

Authors:  Manole Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Buchar)       Date:  2011-10

4.  Study on clinical features and complications with systemic lupus erythematosus (SLE) activity in Chinese Han population.

Authors:  Lian Hong Li; Hai Feng Pan; Wen Xian Li; Xiang Pei Li; Jian Hua Xu; Dong Qing Ye
Journal:  Clin Rheumatol       Date:  2009-08-07       Impact factor: 2.980

5.  Metabolic alterations and increased liver mTOR expression precede the development of autoimmune disease in a murine model of lupus erythematosus.

Authors:  Laia Vilà; Núria Roglans; Miguel Baena; Emma Barroso; Marta Alegret; Manuel Merlos; Juan C Laguna
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.